Tag Archives: agn

Acorda, Allergan Make Surprise Deal On Ampyra Patent

Biotech Acorda Therapeutics (ACOR) said Monday that it had reached a settlement with Actavis, the generic-drug arm of Allergan (AGN), agreeing that Actavis’ generic version of Acorda’s drug Ampyra won’t come out until 2027. Acorda stock rose sharply while Allergan’s fell. The news, which was revealed only through a terse SEC filing, came as a big surprise to Wall Street. Most had expected the generic version of Acorda’s multiple-sclerosis drug to

Allergan Guidance Update Gets Mixed Reception

Shares of specialty-drug giant Allergan (AGN) were seesawing Tuesday after the company issued guidance late Monday for the rest of the year following the sale of its generics business. Allergan said it expects second-half revenue of around $8 billion, with EPS of $6.25 to $6.65, including $750 million in interest expenses. The company said that longer term, it expects 10% growth in its branded product sales and gross profit margins of 77% to 79%.

Amgen, Allergan Biosimilar Avastin Hits In Trial

Big drugmakers Amgen (AMGN) and Allergan (AGN) announced Wednesday that their biosimilar version of Roche’s (RHHBY) blockbuster cancer drug Avastin succeeded in a late-stage trial against non-small-cell lung cancer. Amgen and Allergan, which started their collaboration back in 2011 when Allergan was a generic drug maker called Watson Pharmaceuticals, released few details but said the drug ABP 215 had shown clinical equivalence to Avastin as